Mounjaro once a month for maintenance — what the dosing schedule really means

Is a monthly injection ever the right plan?

This question comes up more often than you might expect, usually driven by cost or by a sense that once the weight is stable, treatment can wind down. It is a completely understandable instinct. But the evidence points the other way.

Tirzepatide (the active medicine in Mounjaro) works by activating GIP and GLP-1 receptors that regulate appetite, slow gastric emptying and influence how the body uses energy. Those receptors don't stay switched on between doses; the medicine needs to be present consistently to keep doing its job. The licensed dosing is once a week precisely because that is the interval at which the pharmacology was shown to work in large-scale trials, and it is the schedule the NHS medicines information for tirzepatide reflects.

Stretching injections to monthly would not be a conservative version of the same treatment, it would be a different, unstudied approach. Weight regain after stopping GLP-1 medicines is well documented, and the same biology applies to large gaps between doses. Your prescriber can talk through what the evidence shows, but the short answer is: once a month is not the maintenance schedule, and it is not one you should move to without a clinical conversation.

What does the maintenance phase actually change?

During the titration phase, your dose increases roughly every four weeks (from 2.5 mg through 5, 7.5, 10 and 12.5 mg, up to a maximum of 15 mg) until you reach the highest dose that suits your body and your treatment goals. Maintenance begins when that upward movement stops. If you are curious about how the very first step fits into that picture, the page on whether 2.5 mg can serve as a maintenance dose explains where that starting strength sits in the overall plan.

What changes in maintenance is the dose-adjustment process, not the weekly rhythm. You stay on your maintenance dose, keep injecting once a week, and continue the lifestyle changes (reduced calorie intake and regular activity) that are part of the licensed programme. The mounjaro maintenance dose page goes into more depth on how that level is determined and what it typically looks like across the dose range.

One thing that sometimes surprises people: the maintenance dose is not always 15 mg. For many people, an earlier dose does the job (7.5 mg or 10 mg, for instance) and there is no clinical reason to push higher if weight is stable and side effects are acceptable. The right maintenance dose is the one that works for you specifically, not the highest on the card. If you are still wondering whether a particular strength counts as a maintenance dose, the page on whether 7.5 mg counts as a maintenance dose addresses that directly, and there is a similar explanation available for those asking whether 5 mg Mounjaro counts as a maintenance dose.

The practical decision: how long to stay on maintenance

NICE's recommendation for tirzepatide (TA1026) includes a review point at six months on the highest tolerated dose: if weight loss is less than 5% at that point, the clinical benefit is reviewed. Outside that checkpoint, NICE does not set a fixed time limit on tirzepatide treatment the way it does for semaglutide under NICE TA1026. That means, for many people, maintenance on Mounjaro is an open-ended phase, continued as long as the medicine is working, tolerated and clinically appropriate.

The honest decision you face in maintenance is not really about frequency. It is about whether to continue, at what dose, and what your weight and health goals look like over the coming months. Cost is a real factor (a look at the Mounjaro cost context in the UK sets out what drives private pricing), and for those trying to understand the pricing of lower doses in particular, the page covering 1mg Mounjaro gives useful context on how dose strength relates to cost. The answer to cost pressure is a conversation about whether your dose can be stepped back, not spacing injections further apart without clinical input.

Mounjaro is a prescription-only medicine. A prescriber decides the schedule; the weekly injection is not optional at the maintenance stage any more than it is during titration. If you want to explore what the long-term plan might look like for your situation, that conversation starts with a clinical assessment.

What to watch during long-term maintenance

Most people find that side effects settle considerably once the titration phase is complete. Nausea, the most common early complaint, tends to ease at a stable dose. That said, it is worth knowing the signals that always warrant prompt medical attention: severe stomach pain that radiates to the back (a possible indicator of pancreatitis) should be assessed the same day. Gallbladder symptoms, signs of dehydration after a bout of vomiting or diarrhoea, and any allergic reaction are also reasons to seek help rather than wait.

During maintenance, clinical reviews are still important. At nume, every repeat order is reviewed by a prescriber before it is dispensed, not a one-time check at the start of treatment, but an ongoing assessment. That is where questions about your current dose, how your weight is tracking and any new symptoms get properly considered. Our clinical team can answer questions about what long-term maintenance monitoring typically involves. If you have general questions about the programme, the FAQs cover many of the most common ones.

If you are thinking about whether Mounjaro is the right long-term option for you, or whether your current situation makes you eligible, check your eligibility with a free consultation, reviewed the same day by a GPhC-registered prescriber.